Brought to you by 
MedImmune spins off Viela Bio with focus on autoimmune therapies
25 Mar 2021
Executive Summary
AstraZeneca PLC and its MedImmune LLC division have spun off a new company, Viela Bio, which will be tasked with developing six autoimmune and inflammatory disease candidates. Though operating as an independent entity, Viela’s largest minority shareholder will be AZ.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Divestiture/Spin-Out
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MedImmune spins off Viela Bio with focus on autoimmune therapies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice